It has been confirmed that Baicalin has anti-bacterial, antiviral and anti-inflammatory activities in vitro. It also can inhibit platelet aggregation and eliminate oxygen-free radicals. Animal experiments show that Baicalin could reduce the generation of endotoxin. In addition, Baicalin has potent effect in inhibiting pancreatin which is the initial metabolite of Baicalin. All these pharmacologic actions can inhibit SAP during its multiple stages.
The research team led by Dr. Zhang Xiping from the first people's hospital of Hangzhou and second affiliated hospital of Zhejiang university spent more than five years working with experimental SAP of rats by the intravenous injection of Baicalin treatment. With the large dosage of baicalin treatment, the rats' survival rate, renal function indexes, renal gross changes and lightmicroscopic changes and its severity scores was greatly improved in end. The article clarified that the therapeutic mechanisms might be related to the inhibition of inflammatory mediators and induction of renal cells apoptosis by the application of tissue microarray technique.
Compared with the Octreotide, the most effective drug in the treatment of SAP, the large dosage Baicalin has equally effective as octreotide in terms of reduction of renal pathological alterations of rats with SAP. But for Octreotide, It is difficult to popularize especially in remote areas with poor economy since it features high price, short half-life and inconvenient administration, while Baicalin features low price, extensive routes of administration and preparation, multiple pharmacologic actions and precise therapeutic effects.
So the Baicalin might be a promising therapeutic medicines in the treatment of SAP despite there are still many works to be done future.